# A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis

> **NCT00217295** · PHASE2 · UNKNOWN · sponsor: **Multiple Sclerosis Institute** · enrollment: 30 (—)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Avonex and Topamax

## Key facts

- **NCT ID:** NCT00217295
- **Lead sponsor:** Multiple Sclerosis Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-04
- **Primary completion:** —
- **Final completion:** 2007-12
- **Target enrollment:** 30 (—)
- **Last updated:** 2005-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00217295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00217295, "A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00217295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*